CooperCompanies Posts $159M Free Cash Flow, $92M Stock Buyback
CooperCompanies generated $159 million in free cash flow in Q1 2026, repurchasing $92 million of shares and raising earnings and FCF guidance. CooperVision delivered 10% calendar Q4 growth driven by shipment timing, while CooperSurgical's fertility unit shows early market recovery.
1. Q1 Financial Performance
CooperCompanies exceeded the top end of its Q1 guidance, generating $159 million in free cash flow and repurchasing $92 million of shares. Management raised full-year earnings-per-share and free cash flow forecasts following the strong quarter.
2. Business Segment Trends
CooperVision reported 10% calendar Q4 revenue growth due to shifted product shipments, while its MyDay launch is gaining traction in the Americas and EMEA. CooperSurgical’s fertility business saw early market recovery signs, and Asia Pacific growth is expected to resume by fiscal Q3 as new products roll out.
3. Strategic Initiatives and Outlook
The strategic review announced in December remains in progress with no definitive updates, creating some investor uncertainty. Operating margins benefited from synergies and cost discipline, tariffs are estimated at $24 million for the year, and the company extended market share gains to an 18th consecutive year.